Sickle Cell Disease Treatment Market To Witness A Customized Procurement Strategy At A CAGR Of 6.0%

The Sickle Cell Disease Treatment Market is slated to grow at a gracious rate of 6.0%, reaching US$ 584.0 Mn by the year 2025. With value-oriented approach being the need of the hour, the healthcare vertical is likely to go the technologically advanced way in the next 10 years. With Big Data, AI comprising these advancements, the healthcare vertical is bound to create greater strides going forward.

Global sickle cell disease treatment market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by increasing adoption of therapies, growing awareness regarding the sickle cell disease treatment in MEA region.

"Sickle Cell Disease Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)" is the new report published by Persistence Market Research for the projected period of 8-years, i.e. 2017-2025.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/16099

Company Profiles:

AstraZeneca Plc.
Eli Lilly and Company
Bristol-Myers Squibb Company
Novartis AG
Pfizer Inc.
Baxter International Inc.
Emmaus Life Sciences, Inc.
Bluebird bio, Inc.
Global Blood Therapeutics Inc.
Sangamo Therapeutics, Inc.
Acceleron Pharma, Inc.
Arena Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Others.

According to this report, the global sickle cell disease treatment market is projected to expand at a CAGR of 6.0 % in terms of value during the forecast period to reach US$ 584.0 Mn by 2025. There is an increased opportunity of the development of the global sickle cell disease treatment market due to drug approvals and drugs in the pipeline which are expected to enter the market in the coming five years.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/16099

Global Sickle Cell Disease Treatment Market: Drivers

Increasing discretionary research funding for Sickle cell anaemia in developed countries
Governments focus on creating awareness on sickle cell anemia cure

Aging population in developed economies and rising affluence in emerging markets to boost healthcare spending

Demand for drug therapy in combination with surgeries and blood transfusion

Changes in lifestyle to increase the probability of genomic mutations

Increasing penetration of FDA approved drugs in the market

Various key players in the sickle cell disease treatment market are signing partnerships and licensing deals to share the research and development platform

Reduction of overall diagnosis cost for sickle cell diseases

Global Sickle Cell Disease Treatment Market: Forecast by Drug Type

On the basis of drug type, the global sickle cell disease treatment market is segmented into hydroxyurea, antibiotics, pain-relieving medications, and Others.

The hydroxyurea segment is likely to be accounted for 38.7 % market revenue share in 2017, which is expected to increase to 35.7% by 2025 end. This drug type is expected to account for a high revenue contribution in the global sickle cell disease treatment market as compared to other drug types over the forecast period.

Hydroxyurea product is expected to be the second attractive drug type segment in sickle cell disease treatment market, with market attractiveness index of 1.2.

Global Sickle Cell Disease Treatment Market: Forecast by Disease Type

On the basis of disease type, the global sickle cell disease treatment market is segmented into sickle cell anemia, sickle hemoglobin C disease, and sickle beta thalassemia. Sickle cell anemia is expected to be the most lucrative among all disease type segment of sickle cell disease treatment market, with attractiveness index of 1.8.

Sickle Beta Thalassemia is expected to be the second attractive drug type segment in sickle cell disease treatment market, with market attractiveness index of 0.7.

Global Sickle Cell Disease Treatment Market: Forecast by Distribution Channel

This segment include hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of drugs by governments to ensure availability in hospital pharmacies.

Hospital pharmacies is expected to be the most lucrative among all distribution channels of sickle cell disease treatment market, with attractiveness index of 2.5. Retail pharmacies is expected to be the second largest distribution channels of sickle cell disease treatment market, with market attractiveness index of 0.4

Access Full Report @ https://www.persistencemarketresearch.com/checkout/16099

Global Sickle Cell Disease Treatment Market: Forecast by Region

Five regions such as North America, Latin America, Europe, APAC and MEA are covered in this report. MEA regions are pegged to represent the most lucrative markets, owing to the high prevalent cases of sickle cell diseases.

The MEA sickle cell disease treatment market is expected to expand at a CAGR of 6.1 % in terms of value over the forecast period. Growing awareness and adoption of treatment for sickle cell disease in India and in the APAC region is expected to create a sizeable opportunity for the players in this market.

Access Related Reports-

Compression Socks Market: https://www.persistencemarketresearch.com/market-research/compression-socks-market.asp

Spinal Cord Trauma Treatment Market: https://www.persistencemarketresearch.com/market-research/spinal-cord-trauma-treatment-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.